High-power short-duration radiofrequency ablation of typical atrial flutter

Mehrdad Golian; F Daniel Ramirez; Wael Alqarawi; Simon P Hansom; Pablo B Nery; Calum J Redpath; Girish M Nair; George C Shaw; Darryl R Davis; David H Birnie; Mouhannad M Sadek

doi:10.1016/j.hroo.2020.09.002

High-power short-duration radiofrequency ablation of typical atrial flutter

Heart Rhythm O2. 2020 Oct 3;1(5):317-323. doi: 10.1016/j.hroo.2020.09.002. eCollection 2020 Dec.

Authors

Affiliations

¹ Arrhythmia Service, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Canada.
² School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
³ Arrhythmia Service, Cardiovascular Institute, Allegheny Health Network, Pittsburgh, Pennsylvania.
⁴ Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada.

Abstract

Background: High-power short-duration (HPSD) ablation has been explored for pulmonary vein isolation. Early data suggest similar efficacy with shorter procedure times and perhaps greater safety. Data are lacking on the use of this ablation strategy for other arrhythmias.

Objective: The purpose of this study was to evaluate the safety, efficacy, and clinical outcomes of HPSD ablation in patients with typical atrial flutter compared to those undergoing ablation with conventional settings.

Methods: Consecutive patients undergoing cavotricuspid isthmus (CTI) ablation using standard power settings were compared to those performed after transitioning to HPSD ablation. Demographics, procedural details, and ablation outcomes were prospectively collected. The primary endpoint was duration of radiofrequency energy delivery. Secondary endpoints were radiation duration and analgesia requirements.

Results: A total of 114 consecutive subjects undergoing CTI ablation (57 standard power, 57 HPSD) were included. HPSD ablation and electroanatomic mapping/contact force (EAM/CF) use were associated with 66% (95% confidence interval [CI] 58%-73%) and 50% (95% CI 37%-60%) shorter ablation times compared to standard power and not using EAM/CF, respectively. Patients in the HPSD group required 50 mcg less fentanyl relative to the standard ablation arm after adjusting for sex, age, and comorbidities (P = .048). At a median follow-up of 6 months, 4 patients (7%) in the standard arm had recurrence of atrial flutter, compared to none in HPSD group (P = .057).

Conclusion: HPSD is a safe and effective approach to CTI ablation. This strategy may reduce ablation time and analgesia requirements. Larger studies and longer follow-up are needed to further evaluate this strategy.

Keywords: Ablation; Atrial fibrillation; Atrial flutter; Fluoroscopy; High-power short-duration ablation.